The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells ...

Next-generation multispecific antibody, ISB 2301, targets 3 tumor-associated antigens (TAAs) and activates both T cells and natural killer (NK) ...

Artiva advances NK cell therapy to phase 3, secures 400 billion won funding Single phase 3 cleared by FDA after strong phase ...

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). The company’s tetraspecific antibody controlled tumors and improved survival in mice and ...

Scientists have developed a strategy to enhance the anticancer power of natural killer cells, which are part of the immune ...

Natural killer (NK) cells are pivotal in the innate immune response against cancer and viral infections, with their presence in tumors correlating to better patient outcomes in various cancers.

Immune cell therapies have transformed the treatment of certain blood cancers over the past decade. However, when it comes to ...

Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo, according ...

A comprehensive analysis published in Reserch illuminates how cancer cells hijack immune checkpoints on natural killer (NK) cells to disable the body’s frontline defense system. The study details: ...

One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be ...